Neurological Biomarkers Market Research Report by Type, by Application, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

Description

List of Tables

The Global Neurological Biomarkers Market size was estimated at USD 6,110.03 million in 2020 and expected to reach USD 6,936.10 million in 2021, at a CAGR 13.85% to reach USD 13,311.72 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Neurological Biomarkers to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Genomic, Imaging, Metabolomic, and Proteomic.

Based on Application, the market was studied across Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson's Disease.

Based on End-user, the market was studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neurological Biomarkers Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neurological Biomarkers Market, including AbaStar MDx, Inc., Abbott Laboratories, Acumen Pharmaceuticals, Alseres Pharmaceuticals, Inc., Athena Diagnostics Inc, Banyan Biomarkers, Inc., Bio-Rad Laboratories, Inc., Diagenic ASA, Imagilys, Invicro. LLC., IXICO plc, Myriad RBM, Proteome Sciences Plc, Psynova Neurotech, Qiagen N.V., Quanterix Corporation, Sigma-Aldrich, Inc, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Neurological Biomarkers Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neurological Biomarkers Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neurological Biomarkers Market?
4. What is the competitive strategic window for opportunities in the Global Neurological Biomarkers Market?
5. What are the technology trends and regulatory frameworks in the Global Neurological Biomarkers Market?
6. What is the market share of the leading vendors in the Global Neurological Biomarkers Market?
7. What modes and strategic moves are considered suitable for entering the Global Neurological Biomarkers Market?

Product Code: MRR-AD36CD897EFB

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

3.1. Introduction

4. Market Overview

4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics

5.1. Introduction
5.2. Drivers
- 5.2.1. Growing prevalence of neurological disorders
- 5.2.2. Demand for cost-effective and non-invasive diagnostic system
- 5.2.3. Increasing preferences on early diagnosis & preventive treatment
5.3. Restraints
- 5.3.1. Stringent government regulations for approvals
5.4. Opportunities
- 5.4.1. Growing R&D focus for advancements in biomarkers
- 5.4.2. Emerging single-cell biosensors
- 5.4.3. Growth of low-cost clinical trials in developing countries
5.5. Challenges
- 5.5.1. Ethical problems and acceptance issues of neurological disorders

6. Neurological Biomarkers Market, by Type

6.1. Introduction
6.2. Genomic
6.3. Imaging
6.4. Metabolomic
6.5. Proteomic

7. Neurological Biomarkers Market, by Application

7.1. Introduction
7.2. Alzheimer's Disease
7.3. Autism Spectrum Disorders
7.4. Multiple Sclerosis
7.5. Parkinson's Disease

8. Neurological Biomarkers Market, by End-user

8.1. Introduction
8.2. Hospital Laboratories
8.3. Independent Clinical Diagnostic Centers
8.4. Research Organizations

9. Americas Neurological Biomarkers Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Neurological Biomarkers Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand

11. Europe, Middle East & Africa Neurological Biomarkers Market

11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
- 12.1.1. Quadrants
- 12.1.2. Business Strategy
- 12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
- 12.4.1. Merger & Acquisition
- 12.4.2. Agreement, Collaboration, & Partnership
- 12.4.3. New Product Launch & Enhancement
- 12.4.4. Investment & Funding
- 12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles

13.1. AbaStar MDx, Inc.
13.2. Abbott Laboratories
13.3. Acumen Pharmaceuticals
13.4. Alseres Pharmaceuticals, Inc.
13.5. Athena Diagnostics Inc
13.6. Banyan Biomarkers, Inc.
13.7. Bio-Rad Laboratories, Inc.
13.8. Diagenic ASA
13.9. Imagilys
13.10. Invicro. LLC.
13.11. IXICO plc
13.12. Myriad RBM
13.13. Proteome Sciences Plc
13.14. Psynova Neurotech
13.15. Qiagen N.V.
13.16. Quanterix Corporation
13.17. Sigma-Aldrich, Inc
13.18. Thermo Fisher Scientific Inc.

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing